Silence Therapeutics plc

Based in London, Silence Therapeutics plc is a UK-incorporated biotechnology company focused on developing RNA interference (siRNA) therapeutics targeting hematological, cardiovascular, and rare diseases. The company's approach uses short interfering RNA molecules to inhibit expression of specific disease-associated genes. Its lead candidate, Zerlasiran (SLN360), is in Phase II clinical development for cardiovascular disease associated with elevated lipoprotein(a). Additional programs include Divesiran (SLN124), a Phase I-stage siRNA molecule for genetic hematological conditions such as polycythemia vera, and SLN548 targeting complement-mediated disease.

Silence Therapeutics operates through two primary collaborations that form significant parts of its business model. The company holds a development and commercialization agreement with AstraZeneca for siRNA therapeutics in cardiovascular, renal, metabolic, and respiratory diseases. Additionally, it maintains a separate collaboration with Hansoh Pharmaceutical Group Company Limited focused on siRNA development.

The company operates with a workforce of approximately 116 full-time employees. Silence Therapeutics is listed on Nasdaq and maintains a market capitalization of approximately $0.3 billion.